Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Jun. 30, 2018 | Aug. 29, 2018 | |
Document And Entity Information | ||
Entity Registrant Name | Replimune Group, Inc. | |
Entity Central Index Key | 1,737,953 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Entity Current Reporting Status | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 31,553,672 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q1 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 12,910 | $ 17,583 |
Short-term investments | 39,119 | 43,968 |
Research and development incentives receivable | 2,251 | 2,389 |
Prepaid expenses and other current assets | 944 | 763 |
Total current assets | 55,224 | 64,703 |
Property, plant and equipment, net | 443 | 370 |
Deferred offering costs | 1,344 | |
Research and development incentives receivable - long term | 426 | |
Restricted cash | 1,856 | 78 |
Total assets | 59,293 | 65,151 |
Current liabilities: | ||
Accounts payable | 2,854 | 1,993 |
Accrued expenses and other current liabilities | 1,642 | 3,171 |
Total current liabilities | 4,496 | 5,164 |
Deferred rent, net of current portion | 43 | 52 |
Warrant liability | 7,092 | 1,642 |
Total liabilities | 11,631 | 6,858 |
Commitments and contingencies (Note 13) | ||
Convertible preferred stock (Series Seed, A and B), $0.001 par value; 1,975,968 shares authorized as of June 30, 2018 and March 31, 2018; 1,925,968 shares issued and outstanding as of June 30, 2018 and March 31, 2018 | 86,361 | 86,361 |
Stockholders' Deficit: | ||
Common stock, $0.001 par value; 27,314,288 shares authorized (inclusive of 26,258 shares of common A stock) as of June 30, 2018 and March 31, 2018; 5,007,485 shares issued and outstanding (inclusive of 26,258 shares of common A stock) as of June 30, 2018 and March 31, 2018 | 5 | 5 |
Additional paid-in capital | 1,322 | 1,097 |
Accumulated deficit | (38,976) | (28,932) |
Accumulated other comprehensive loss | (1,050) | (238) |
Total stockholders' deficit | (38,699) | (28,068) |
Total liabilities, convertible preferred stock and stockholders' deficit | $ 59,293 | $ 65,151 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2018 | Mar. 31, 2018 |
Convertible preferred stock (series seed, A and B), par value (in dollars per share) | $ 0.001 | $ 0.001 |
Convertible preferred stock (series seed, A and B), authorized | 1,975,968 | 1,975,968 |
Convertible preferred stock (series seed, A and B), issued | 1,925,968 | 1,925,968 |
Convertible preferred stock (series seed, A and B), outstanding | 1,925,968 | 1,925,968 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized | 27,314,288 | 27,314,288 |
Common stock, issued | 5,007,485 | 5,007,485 |
Common stock, outstanding | 5,007,485 | 5,007,485 |
Common A stock | ||
Common stock, authorized | 26,258 | 26,258 |
Common stock, issued | 26,258 | 26,258 |
Common stock, outstanding | 26,258 | 26,258 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Operating expenses: | ||
Research and development | $ 3,936 | $ 2,291 |
General and administrative | 1,943 | 885 |
Total operating expenses | 5,879 | 3,176 |
Loss from operations | (5,879) | (3,176) |
Other income (expense): | ||
Research and development incentives | 438 | 467 |
Interest income | 227 | 30 |
Change in fair value of warrant liability | (5,450) | |
Other income (expense), net | 620 | (873) |
Total other income (expense), net | (4,165) | (376) |
Net loss | (10,044) | (3,552) |
Net loss attributable to common stockholders | $ (10,044) | $ (3,552) |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (2.02) | $ (0.71) |
Weighted average common shares outstanding, basic and diluted (in shares) | 4,981,227 | 4,973,439 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Consolidated Statements of Comprehensive Loss | ||
Net loss | $ (10,044) | $ (3,552) |
Other comprehensive income (loss): | ||
Foreign currency translation gain (loss) | (847) | 953 |
Net unrealized gain on short-term investments, net of tax | 35 | |
Comprehensive loss | $ (10,856) | $ (2,599) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Cash flows from operating activities: | ||
Net loss | $ 10,044 | $ 3,552 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense | 225 | 45 |
Depreciation and amortization | 33 | 23 |
Change in fair value of warrant liability | 5,450 | |
Net amortization/accretion of premiums and discounts on short-term investments | (121) | |
Changes in operating assets and liabilities: | ||
Research and development incentives receivable | (438) | (468) |
Prepaid expenses and other current assets | (220) | (1,256) |
Accounts payable | (259) | 381 |
Accrued expenses and other current liabilities | (1,479) | (660) |
Deferred rent | (6) | (6) |
Net cash used in operating activities | (6,859) | (5,493) |
Cash flows from investing activities: | ||
Purchases of property, plant and equipment | (116) | (33) |
Purchases of short-term investments | (10,744) | |
Sales and maturities of short-term investments | 15,750 | |
Net cash provided by (used in) investing activities | 4,890 | (33) |
Cash flows from financing activities: | ||
Payment of issuance costs | (195) | |
Net cash used in financing activities | (195) | |
Effect of exchange rate changes on cash and cash equivalents | (731) | 898 |
Net decrease in cash | (2,895) | (4,628) |
Cash, cash equivalents and restricted cash at beginning of period | 17,661 | 20,669 |
Cash, cash equivalents and restricted cash at end of period | 14,766 | $ 16,041 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Deferred offering costs included in accounts payable | 1,149 | |
Purchases of property and equipment included in accounts payable | $ 21 |
Nature of the business
Nature of the business | 3 Months Ended |
Jun. 30, 2018 | |
Nature of the business | |
Nature of the business | 1. Nature of the business Replimune Group, Inc. (the “Company”) is a clinical‑stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. Replimune Limited (“Replimune UK”) was incorporated in 2015 under the laws of England, and was the sole shareholder of Replimune, Inc. (“Replimune US”), a Delaware corporation. On July 5, 2017, Replimune Group, Inc., a Delaware corporation, was incorporated and on July 10, 2017 the shareholders of Replimune UK effected a share‑for‑share exchange pursuant to which they exchanged their outstanding shares in Replimune UK for shares in Replimune Group, Inc., on a one‑for‑one basis. In addition, the holders of warrants and stock options to purchase Replimune UK capital stock canceled their warrants to purchase shares of series seed preferred stock and stock options in Replimune UK and were issued replacement warrants to purchase shares of series seed preferred stock and stock options to acquire Replimune Group, Inc. capital stock on a one‑for‑one basis. These transactions are collectively referred to as the reorganization. Upon completion of the reorganization, the historical consolidated financial statements of Replimune UK became the historical consolidated financial statements of Replimune Group, Inc. because the reorganization was accounted for similar to a reorganization of entities under common control due to the high degree of common ownership of Replimune UK and Replimune Group, Inc. and lack of economic substance to the transaction. The Company concluded that the reorganization resulted in no change in the material rights and preferences of each respective class of equity interests and no change in the fair value of each respective class of equity interests before and after the reorganization. On December 8, 2017, Replimune UK transferred all outstanding shares of its wholly owned subsidiary, Replimune US to Replimune Group, Inc. Replimune Group. Inc., a Delaware corporation, is the sole shareholder of Replimune UK, Replimune US and Replimune Securities Corporation, a Massachusetts corporation that was incorporated in November 2017. The Company is subject to risks and uncertainties common to early‑stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Forward stock split On July 9, 2018, the Company effected a 1-for-9.94688 forward stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's Preferred Stock (see Note 7). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this forward stock split and adjustment of the preferred stock conversion ratios. Further, on July 9, 2018, the Company's authorized shares of common stock were increased to 27,314,288. Accordingly, the authorized shares of common stock presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the newly authorized shares of common stock. Initial public offering On July 24, 2018, the Company completed an initial public offering (“IPO”) of its common stock and issued and sold 6,700,000 shares of common stock at a public offering price of $15.00 per share, resulting in net proceeds of $93,465 after deducting underwriting discounts and commissions but before deducting offering costs. Upon closing of the IPO, the Company’s outstanding convertible preferred stock automatically converted into shares of common stock (see Note 7). Upon conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock and additional paid-in capital. In addition, the warrant to purchase shares of the Company’s series seed convertible preferred stock was converted into a warrant to purchase shares of the Company’s common stock upon the closing of the IPO. As a result, the warrant liability will be remeasured a final time on the closing date of the IPO and reclassified to stockholders’ deficit. On July 30, 2018, the Company issued and sold an additional 707,936 shares of its common stock at the IPO price of $15.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $9,876 after deducting discounts and commissions and other offering expenses. Also in connection with the completion of its IPO on July 24, 2018, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to authorize the issuance of up to 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. Basis of presentation The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through June 30, 2018, the Company has funded its operations primarily with proceeds from the sale of convertible preferred stock. The Company has incurred recurring losses since its inception, including net losses of $10,044 and $3,552 for the three months ended June 30, 2018 and 2017, respectively. In addition, as of June 30, 2018, the Company had an accumulated deficit of $38,976. The Company expects to continue to generate operating losses for the foreseeable future. As of August 30, 2018, the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments, including the net proceeds from the IPO, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain funding it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or it may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. |
Summary of significant accounti
Summary of significant accounting policies | 3 Months Ended |
Jun. 30, 2018 | |
Summary of significant accounting policies | |
Summary of significant accounting policies | 2. Summary of significant accounting policies Principles of consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Replimune UK, Replimune US and Replimune Securities Corporation, after elimination of all intercompany accounts and transactions. The consolidated financial statements reflect the capital as if Replimune Group, Inc. had been in existence for all periods presented. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock‑based awards. The Company bases its estimates on historical experience, known trends and other market‑specific or other relevant factors that it believe to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Unaudited interim consolidated financial information The accompanying consolidated balance sheet as of June 30, 2018, the consolidated statements of operations, of comprehensive loss and of cash flows for the three months ended June 30, 2018 and 2017 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2018 and the results of its operations and its cash flows for the three months ended June 30, 2018 and 2017. The financial data and other information disclosed in these consolidated notes related to the three months ended June 30, 2018 and 2017 are unaudited. The results for the three months ended June 30, 2018 are not necessarily indicative of results to be expected for the year ending March 31, 2019, any other interim periods or any future year or period. Foreign currency and currency translation The functional currency for the Company’s wholly owned foreign subsidiary, Replimune UK, is the British pound. Assets and liabilities of Replimune UK are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of convertible preferred stock and stockholders’ deficit as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations as incurred. Concentrations of credit risk and of significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as short‑term investments. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials. Cash and cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. Cash equivalents consisted of money market funds at June 30, 2018 and March 31, 2018. As of June 30, 2018 and March 31, 2018, cash equivalents totaled $4,194 and $4,130, respectively. Restricted cash The Company maintains certain minimum balances in segregated bank accounts in connection with its corporate credit cards and a letter of credit for the benefit of the landlords in connection with an operating lease. As of June 30, 2018 and March 31, 2018, restricted cash consisted of $76 and $78, respectively, held in connection with the Company’s corporate credit cards and $1,780 and $0, respectively, held for the benefit of the landlords in connection with an operating lease. These amounts have been classified as non‑current assets on the Company’s consolidated balance sheets. Short‑term investments The Company’s short‑term debt security investments are classified as available‑for‑sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ deficit. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations. The Company evaluates its short‑term debt security investments with unrealized losses for other‑than‑temporary impairment. When assessing short‑term debt security investments for other‑than‑temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain the short‑term debt security investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the short‑term debt security investment that the Company considers to be “other than temporary,” the Company reduces the short‑term debt security investment to fair value through a charge to the consolidated statements of operations. No such adjustments were necessary during the periods presented. The Company’s short‑term debt security investments as of June 30, 2018 and March 31, 2018 had original maturities of less than one year. Deferred offering costs The Company capitalizes certain legal, professional accounting and other third‑party fees that are directly associated with in‑process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit as a reduction of proceeds generated as a result of the offering. Should an in‑process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. The Company did not record any deferred offering costs as of March 31, 2018. As of June 30, 2018, the Company recorded $1,344 of deferred offering costs in contemplation of a planned initial public offering of common stock. Property, plant and equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight‑line method over the estimated useful lives of the respective assets as follows: Estimated Useful life Office equipment 5 years Computer equipment 3 years Plant and laboratory equipment 5 years Leasehold improvements Lesser of lease term or 10 years Costs for capital assets not yet placed into service are capitalized as construction‑in‑progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. Impairment of long‑lived assets Long‑lived assets consist of property, plant and equipment. Long‑lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long‑lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long‑lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long‑lived assets. Deferred rent The Company recognizes rent expense on a straight‑line basis over the respective lease terms and has recorded deferred rent for rent expense incurred but not yet paid. Fair value measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: · Level 1—Quoted prices in active markets for identical assets or liabilities. · Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. · Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s short‑term investments, cash equivalents and warrant liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of research and development incentives receivable, other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short‑term nature of these assets and liabilities. Warrant liability The Company classifies warrants to purchase shares of series seed preferred stock (see Note 8) as a liability on its consolidated balance sheets as these warrants to purchase shares of series seed preferred stock are free‑standing financial instruments that may require the Company to transfer assets upon exercise. The warrant liability was initially recorded at fair value upon the date of the warrants’ issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Changes in the fair value of the warrant liability will continue to be recognized until the warrants to purchase shares of series seed preferred stock are exercised, expire or qualify for equity classification. The Company utilizes the Black‑Scholes option‑pricing model, which incorporates assumptions and estimates, to value the warrant liability. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the expected stock price volatility, the expected term of the warrant, the risk‑free interest rate for a period that approximates the expected term of the warrant, and the Company’s expected dividend yield (see Note 3). Upon the closing of the IPO, the warrant to purchase shares of the Company’s series seed convertible preferred stock was converted into a warrant to purchase shares of the Company’s common stock. As a result, the warrant liability will be remeasured a final time on the closing date of the IPO and reclassified to stockholders’ deficit. Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s current focus is on developing oncolytic immunotherapies for the treatment of cancer. Research and development costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock‑based compensation and benefits, facilities costs and laboratory supplies, depreciation and external costs of outside vendors engaged to conduct preclinical development, clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non‑refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. Research contract costs and accruals The Company has entered into various research and development-related contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs All patent‑related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock‑based compensation The Company measures all stock‑based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black‑Scholes option‑pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk‑free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield (see Note 10). Forfeitures are accounted for as they occur. To date, the Company has issued stock‑based awards with only service‑based vesting conditions and records the expense for these awards using the straight‑line method. For stock‑based awards granted to consultants and non‑employees, compensation expense is recognized over the shorter of the vesting period or the period during which services are rendered by such consultants and non‑employees until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then‑current fair value of the Company’s common stock and updated assumption inputs in the Black‑Scholes option‑pricing model. The Company classifies stock‑based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Research and development incentives and receivable The Company, through its subsidiary in the United Kingdom, receives reimbursements of certain research and development expenditures as part of a United Kingdom government’s research and development tax reliefs program. Under the program, a percentage of qualifying research and development expenses incurred by the Company’s subsidiary in the United Kingdom are reimbursed up to 14.5%. Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as other income. The research and development incentives receivable represents an amount due in connection with the above program. The Company recorded other income from research and development incentives of $438 and $467 during the three months ended June 30, 2018 and 2017, respectively, in the consolidated statements of operations and a research and development incentives receivable of $2,677 (of which $2,251 was classified as current and $426 was classified as long-term) and $2,389 as of June 30, 2018 and March 31, 2018, respectively, on the consolidated balance sheets. Comprehensive loss Comprehensive loss includes net loss as well as other changes in stockholders’ deficit that result from transactions and economic events other than those with stockholders. For the three months ended June 30, 2018 and 2017, comprehensive loss included $(847) and $953 of foreign currency translation adjustments, and $35 and $0 of unrealized gains on short‑term investments, net of tax, respectively. Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two‑step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more‑likely‑than‑not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net income (loss) per share The Company follows the two‑class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two‑class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two‑class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. Common A shares are excluded when computing net income (loss) per share as they have nominal economic rights. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but contractually do not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti‑dilutive. Recently adopted accounting pronouncements In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU 2017-09"), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2017-09 as of the required effective date of April 1, 2018 and will apply to any changes to the terms or conditions of share-based payment awards prospectively. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash ("ASU 2016-18"), which requires restricted cash to be presented with cash and cash equivalents on the consolidated statements of cash flows and disclosure of how the consolidated statements of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-18 as of April 1, 2018. Restricted cash is now included as a component of cash, cash equivalents and restricted cash on the Company's consolidated statement of cash flows. Upon the adoption of ASU 2016-18, the amount of cash and cash equivalents previously presented on the consolidated statements of cash flows will reflect the inclusion of restricted cash in the amount reported for changes in cash, cash equivalents and restricted cash. Additionally, as a result of the adoption, transfers between restricted and unrestricted cash are no longer presented as a component of the Company’s investing activities. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory ("ASU 2016-16"), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-16 as of the required effective date of April 1, 2018. The adoption of ASU 2016-16 did not have a material impact on the Company’s financial position, results of operations or cash flows. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the consolidated statements of cash flows. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-16 as of the required effective date of April 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which supersedes existing revenue recognition guidance under GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December 15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December 15, 2016. The Company adopted ASU 2014-09 on a full retrospective basis effective April 1, 2018. The adoption of ASU 2014-09 did not have an impact on the Company's consolidated financial statements as the Company does not currently have any revenue-generating arrangements. Recently issued accounting pronouncements In July 2017, the FASB issued ASU No. 2017‑11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017‑11”). Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down‑round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (“ASC”) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017‑11 is required to be adopted for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2017-11 is not expected to have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December 15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. In June 2018, the FASB issued (“ASU 2018-07”), Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-17 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-17 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that ASU 2018-17 will ha |
Fair value of financial assets
Fair value of financial assets and liabilities | 3 Months Ended |
Jun. 30, 2018 | |
Fair value of financial assets and liabilities | |
Fair value of financial assets and liabilities | 3. Fair value of financial assets and liabilities The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2018 Using: Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 4,194 $ — $ 4,194 Commercial paper — 22,017 — 22,017 Corporate debt securities — 17,102 — 17,102 $ — $ 43,313 $ — $ 43,313 Liabilities: Warrant liability $ — $ — $ 7,092 $ 7,092 $ — $ — $ 7,092 $ 7,092 Fair Value Measurements as of March 31, 2018 Using: Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 4,130 $ — $ 4,130 Commercial paper — 27,998 — 27,998 Corporate debt securities — 15,970 — 15,970 $ — $ 48,098 $ — $ 48,098 Liabilities: Warrant liability $ — $ — $ 1,642 $ 1,642 $ — $ — $ 1,642 $ 1,642 During the three months ended June 30, 2018 and 2017, there were no transfers between levels. Valuation of cash equivalents and short‑term investments Money market funds, commercial paper and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. Valuation of warrant liability The warrant liability is related to the warrants to purchase shares of series seed preferred stock (see Note 8). The fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company used the Black‑Scholes option‑pricing model, which incorporates assumptions and estimates, to value the warrant liability. Key estimates and assumptions impacting the fair value measurement include (i) the expected term of the warrants, (ii) the risk‑free interest rate, (iii) the expected dividend yield, (iv) expected volatility of the price of the underlying series seed preferred stock and (v) the fair value of the series seed preferred stock on the valuation date. The Company estimated the fair value per share of the underlying series seed preferred stock based, in part, on the results of third‑party valuations and additional factors deemed relevant. The risk‑free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company estimated a 0% expected dividend yield based on the fact that the Company has never paid or declared dividends and does not intend to do so in the foreseeable future. As the Company was a private company as of the date of the valuation of the warrant liability and lacks company‑specific historical and implied volatility information of its stock, the expected stock volatility was based on the historical volatility of publicly traded peer companies for a term equal to the remaining expected term of the warrants. The following table presents the unobservable inputs of the warrant liability: Three Months Ended June 30, 2017 2018 Risk-free interest rate 2.68 % 1.20 % Expected dividend yield 0 % 0 % Expected term (in years) 7.3 8.3 Expected volatility 64.4 % 75.0 % Fair value of series seed preferred stock $ 15.00 $ 1.68 The following table presents a roll forward of the warrant liability: Warrant Liability Balance at March 31, 2018 $ 1,642 Change in fair value 5,450 Balance at June 30, 2018 $ 7,092 |
Short-term investments
Short-term investments | 3 Months Ended |
Jun. 30, 2018 | |
Short-term investments | |
Short-term investments | 4. Short‑term investments Short‑term investments by investment type consisted of the following: June 30, 2018 Amortized Gross Unrealized Gross Unrealized Fair cost Gains Losses value Commercial paper $ 22,033 $ 1 $ (17) $ 22,017 Corporate debt securities 17,116 — (14) 17,102 $ 39,149 $ 1 $ (31) $ 39,119 March 31, 2018 Amortized Gross Unrealized Gross Unrealized Fair cost Gains Losses value Commercial paper $ 28,028 $ 2 $ (32) $ 27,998 Corporate debt securities 16,005 — (35) 15,970 $ 44,033 $ 2 $ (67) $ 43,968 |
Property, plant and equipment,
Property, plant and equipment, net | 3 Months Ended |
Jun. 30, 2018 | |
Property, plant and equipment, net | |
Property, plant and equipment, net | 5. Property, plant and equipment, net Property, plant and equipment, net consisted of the following: June 30, March 31, 2018 2018 Leasehold improvements $ 154 $ 154 Office equipment 49 49 Computer equipment 91 87 Plant and laboratory equipment 438 336 732 626 Less: Accumulated depreciation and amortization (289) (256) $ 443 $ 370 Depreciation and amortization expense was $33 and $23 for the three months ended June 30, 2018 and 2017, respectively. |
Accrued expenses and other curr
Accrued expenses and other current liabilities | 3 Months Ended |
Jun. 30, 2018 | |
Accrued expenses and other current liabilities | |
Accrued expenses and other current liabilities | 6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following: June 30, March 31, 2018 2018 Accrued research and development costs $ 809 $ 949 Accrued compensation and benefits costs 334 949 Accrued professional fees 345 1,094 Deferred rent 25 26 Other 129 153 $ 1,642 $ 3,171 |
Convertible preferred stock
Convertible preferred stock | 3 Months Ended |
Jun. 30, 2018 | |
Convertible preferred stock | |
Convertible preferred stock | 7. Convertible preferred stock The Company has issued series seed convertible preferred stock (the "series seed preferred stock"), series A convertible preferred stock (the "series A preferred stock") and series B convertible preferred stock (the "series B preferred stock"). The series seed preferred stock, series A preferred stock and series B preferred stock are collectively referred to as the "preferred stock." In connection with the closing of the IPO, the preferred stock converted into shares of common stock on a 1:9.94688 basis. As of each balance sheet date, preferred stock consisted of the following: June 30, 2018 Preferred Preferred Shares Common Stock Shares Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series Seed preferred stock 250,000 200,000 $ 1,609 $ 2,000 1,989,376 Series A preferred stock 864,553 864,553 30,000 30,000 8,599,601 Series B preferred stock 861,415 861,415 54,752 54,950 8,568,383 1,975,968 1,925,968 $ 86,361 $ 86,950 19,157,360 March 31, 2018 Preferred Preferred Shares Common Stock Shares Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series Seed preferred stock 250,000 200,000 $ 1,609 $ 2,000 1,989,376 Series A preferred stock 864,553 864,553 30,000 30,000 8,599,601 Series B preferred stock 861,415 861,415 54,752 54,950 8,568,383 1,975,968 1,925,968 $ 86,361 $ 86,950 19,157,360 Prior to the closing of the IPO, the holders of the preferred stock had the following rights and preferences: Voting The holders of the preferred stock were entitled to vote, together with the holders of common stock, on all matters submitted to the stockholders for a vote and were entitled to the number of votes equal to the number of whole shares of common stock into which such holders of preferred stock could convert on the record date of for determination of stockholders entitled to vote. The holders of preferred stock and common stock, voting as a single class, were entitled to elect two directors of the Company. Additionally, the holders of the series seed preferred stock were entitled to elect two directors of the Company, the holders of the series A preferred stock were entitled to elect one director of the Company and the holders of at least 55% of the outstanding series B preferred stock were entitled to elect two directors of the Company. Conversion Each share of preferred stock was convertible into common stock, at any time, at the option of the holder, and without the payment of additional consideration, at the applicable conversion ratio then in effect for each series of preferred stock and subject to adjustment in accordance with anti‑dilution provisions. In addition, each share of preferred stock was convertible into common stock at the applicable conversion ratio then in effect for each series of preferred stock upon the earlier of (i) the closing of a firm commitment underwritten public offering of the Company’s common stock with gross proceeds to the Company of at least $30,000 and at a price per share of not less than $9.62, subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization, or (ii) a date specified by vote or written consent of the holders of 75% of the outstanding preferred stock (voting together as a single class on an as‑converted basis). For any events of deemed liquidation (as defined below) in which series B preferred stock investors would receive less than their full liquidation preference, a further approval of holders of 55% of the outstanding series B preferred stock was required. As of June 30, 2018 and 2017, each share of preferred stock was convertible into 9.94688 share of common stock. The conversion ratio for each series of preferred stock was determined by dividing the original issue price of each series of preferred stock by the conversion price of each series (as defined below). As of June 30, 2018 and March 31, 2018, the series seed preferred stock original issue price and series seed preferred stock conversion price were $1.01 per share and $10.00 per share, respectively. As of June 30, 2018 and March 31, 2018, the series A preferred stock original issue price and series A preferred stock conversion price were $3.49 per share and $34.70 per share, respectively. As of June 30, 2018 and March 31, 2018, the series B preferred stock original issue price and series B preferred stock conversion price were $6.41 per share and $63.79 per share, respectively. Such series seed preferred stock original issue price, series A preferred stock original issue price and series B preferred stock original issue price and series seed preferred stock conversion price, series A preferred stock conversion price and series B preferred stock conversion price, and the rate at which each series of preferred stock may be converted into common stock, were subject to appropriate adjustment from time to time in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred stock. The series seed preferred stock conversion price, series A preferred stock conversion price and series B preferred stock conversion price were also subject to adjustments based on weighted‑average anti‑dilution provisions set forth in the Company’s certificate of incorporation, as amended and restated, in the event that additional securities were issued at a purchase price less than the series seed preferred stock conversion price, series A preferred stock conversion price or series B preferred stock conversion price then in effect. Dividends The holders of the preferred stock were entitled to be paid noncumulative dividends if and when declared by the Company’s board of directors. The Company could not pay any dividends on shares of common stock of the Company unless the holders of preferred stock then outstanding simultaneously receive dividends at the same rate and same time as dividends paid with respect to common stock. Dividends were to accrue on a daily basis assuming a 365‑day year, and were to be paid in cash. Through June 30, 2018 and March 31, 2018, no dividends had been declared or paid. Liquidation preference In the event of any voluntary or involuntary liquidation event, dissolution, winding up of the Company or an event of deemed liquidation, each holder of the then outstanding series B preferred stock would have been entitled to receive, prior and in preference to any distributions to the holders of series A preferred stock, series seed preferred stock and common stock, an amount equal to the greater of (i) the applicable original issue price, plus any declared but unpaid dividends thereon, or (ii) the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. After the payment of all preferential amounts to the holders of series B preferred stock, each holder of the then outstanding series A preferred stock would have been entitled to receive, prior and in preference to any distributions to the holders of series seed preferred stock and common stock, an amount equal to the greater of (i) the applicable original issue price, plus any declared but unpaid dividends thereon, or (ii) the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. After the payment of all preferential amounts to the holders of series A preferred stock, each holder of the then outstanding series seed preferred stock would have been entitled to receive, prior and in preference to any distributions to the holders of common stock, an amount equal to the greater of (i) the applicable original issue price, plus any declared but unpaid dividends thereon or (ii) the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. After payments have been made in full to the holders of preferred stock, then, to the extent available, the remaining amounts would have been distributed among the holders of the shares of common stock, the holders of series B preferred stock and the holders of series A preferred stock, pro rata based on the number of shares held by each holder, assuming full conversion of all such preferred stock. The holders of series B preferred stock and series A preferred stock were subject to a participation cap (as defined below) for remaining amounts that would have been distributed, which was $127.58 per share for the series B preferred stock and $69.40 per share for the series A preferred stock. To the extent available, the remaining amounts greater than the total of the participation caps would have been distributed among the holders of the shares of common stock, pro rata based on the number of shares held by each holder. Unless a majority of the holders of the then outstanding preferred stock, on an as‑if‑converted basis voting together as a single class, elect otherwise, an event of deemed liquidation shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation), sale, transfer or exclusive license of substantially all of the assets of the Company. The preferred stock was conditionally redeemable upon an event of deemed liquidation, which was defined as any (i) merger, consolidation or acquisition, involving the Company or its Subsidiary Undertaking, in which the Company or its subsidiary undertaking was not the surviving entity, (ii) an asset sale, (iii) a share sale, (iv) an initial public offering, (v) the occurrence of a change of control in respect of the Company, (vi) a winding up (vii) or any other a return of capital to stockholders (other than a conversion, redemption or repurchase of shares made in accordance with the applicable governing documents). Redemption The Company’s certificate of incorporation, as amended and restated, did not provide redemption rights to the holders of preferred stock. The holders of shares of convertible preferred stock had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company. Therefore, convertible preferred stock was classified outside of stockholders’ deficit. Upon issuance of each class of preferred stock, the Company assessed the embedded conversion and liquidation features of the securities. The Company determined that each class of preferred stock did not require the Company to separately account for the liquidation features. The Company also concluded that no beneficial conversion feature existed upon the issuance date of the series A preferred stock or series B preferred stock as of June 30, 2018 and March 31, 2018. However, the Company did conclude that a beneficial conversion feature existed upon the issuance date of the series seed preferred stock. As the series seed preferred stock was convertible into common stock, at any time, at the option of the holder, and without the payment of additional consideration, at the applicable conversion ratio then in effect, the Company recognized the accretion of the beneficial conversion feature as a deemed dividend immediately upon the issuance of the series seed preferred stock. |
Preferred stock warrants
Preferred stock warrants | 3 Months Ended |
Jun. 30, 2018 | |
Preferred stock warrants | |
Preferred stock warrants | 8. Preferred stock warrants In connection with the issuance of the series seed preferred stock, the Company issued to the holders of the series seed preferred stock warrants for the purchase of 50,000 shares of series seed preferred stock, which became fully vested and exercisable in the year of issuance. The warrants to purchase shares of series seed preferred stock were issued at an exercise price of $10.00 per share and expire on the earlier of September 16, 2025 or a qualified change of control event. The issuance date fair value of the warrants to purchase shares of series seed preferred stock was $391 and was recorded as a liability with a corresponding reduction in the carrying value of the series seed preferred stock. As of June 30, 2018 and March 31, 2018, the fair value of the warrant liability was $7,092 and $1,642, respectively. The Company recognized a loss of $5,450 and $0 within other income (expense), net in the consolidated statements of operations for the three months ended June 30, 2018 and 2017, respectively, related to the change in fair value of the warrant liability. Upon the closing of the Company’s IPO in July 2018, all outstanding preferred stock was converted into common stock and the series seed preferred stock warrants became exercisable for common stock instead of series seed preferred stock. As a result, the warrant liability will be remeasured a final time on the closing date of the IPO and reclassified to stockholders’ deficit. |
Common stock
Common stock | 3 Months Ended |
Jun. 30, 2018 | |
Common stock | |
Common stock | 9. Common stock As of June 30, 2018 and March 31, 2018, the Company was authorized to issue 27,314,288 shares of par value $0.001 per share common stock (including 26,258 authorized shares of common A stock). In July 2017, the Company issued and sold 26,258 shares of par value $0.001 per share common A stock for nominal cash proceeds. The voting, dividend and liquidation rights of the holders of the Company’s common stock is subject to and qualified by the rights, powers and preferences of the holders of the preferred stock as set forth above. As of June 30, 2018 and March 31, 2018, the Company had reserved 22,306,801 shares of common stock for the conversion of outstanding shares of preferred stock (see Note 7), the exercise of outstanding stock options, the number of shares remaining available for grant under the Company’s 2017 Equity Compensation Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of series seed preferred stock (see Note 8), assuming all warrants to purchase shares of series seed preferred stock became warrants to purchase shares of common stock at the applicable conversion ratio. Voting Each share of common stock, including common A stock, entitles the holder to one vote, together with the holders of preferred stock, on all matters submitted to the stockholders for a vote. The holders of common stock, together with the holders of preferred stock and voting as a single class, are entitled to elect two directors of the Company by vote of a majority of such shares. Dividends Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any, subject to the preferential dividend rights of the preferred stock. Through June 30, 2018 no cash dividends have been declared or paid. Each share of common A stock is entitled to receive dividends, as may be declared by the Company’s board of directors, if any, equal to a maximum of 100% of each share’s par value. Upon an event of deemed liquidation, common A stock is entitled to receive dividends equal to a maximum of 300% of each share’s par value. |
Stock-based compensation
Stock-based compensation | 3 Months Ended |
Jun. 30, 2018 | |
Stock-based compensation | |
Stock-based compensation | 10. Stock‑based compensation 2015 Enterprise Management Incentive Share Option Plan The 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the “2015 Plan”) provided for Replimune UK to grant incentive stock options, non‑statutory stock options, stock awards, stock units, stock appreciation rights and other stock‑based awards. Incentive stock options are granted only to the Company’s employees, including officers and directors who are also employees. Non‑statutory stock options are granted to employees, members of the board of directors, outside advisors and consultants of the Company. 2017 Equity Compensation Plan In July 2017, in conjunction with the Reorganization, the 2015 Plan was terminated and all awards were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the “2017 Plan”). Subsequent to the Reorganization, no additional grants will be made under the 2015 Plan and any outstanding awards under the 2015 Plan will continue with their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award. The Company’s 2017 Plan provides for the Company to grant incentive stock options or non‑statutory stock options, stock awards, stock units, stock appreciation rights and other stock‑based awards. Incentive stock options may be granted only to the Company’s employees, including officers and directors who are also employees. Restricted stock awards and non‑statutory stock options may be granted to employees, officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885 as of June 30, 2018, of which 149,567 remained available for future grants as of June 30, 2018. Shares with respect to which awards have expired, terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2017 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. The 2017 Plan is and the 2015 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. However, the board of directors shall administer and approve all grants made to non‑employee directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not be greater than five years for an incentive stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options awarded under both plans expire ten years after the grant date, unless the board of directors sets a shorter term. Vesting periods for both plans are determined at the discretion of the board of directors. Incentive stock options granted to employees and non‑statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Stock option valuation The fair value of stock option grants is estimated using the Black‑Scholes option‑pricing model. The Company historically has been a private company and lacks company‑specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service‑based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain‑vanilla” options. The expected term of stock options granted to non‑employees is equal to the contractual term of the option award. The risk‑free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company did not grant any stock options during the three months ended June 30, 2018 or 2017. Stock options The following table summarizes the Company’s stock option activity: Weighted Weighted Average Number of Average Contractual Aggregate Shares Exercise Price Term (Years) Intrinsic Value Outstanding as of March 31,2018 2,520,247 $ 2.72 8.91 $ 2,808 Cancelled (17,717) 2.62 Outstanding as of June 30, 2018 2,502,530 $ 2.72 8.66 $ 30,736 Options exercisable as of March 31, 2018 592,416 $ 1.84 8.22 $ 1,184 Options exercisable as of June 30, 2018 647,947 $ 1.81 7.95 $ 8,543 Options vested and expected to vest as of March 31, 2018 2,520,247 $ 2.72 8.91 $ 2,808 Options vested and expected to vest as of June 30, 2018 2,502,530 $ 2.72 8.66 $ 30,736 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The total fair value of options vested during the three months ended June 30, 2018 and 2017 was $45 and $64, respectively. As of June 30, 2018 there were no outstanding unvested service‑based stock options held by non‑employees. Stock‑based compensation Stock‑based compensation expense was classified in the consolidated statements of operations as follows: Three Months Ended June 30, 2018 2017 Research and development $ 126 $ 21 General and administrative 99 24 Total share based compensation expense $ 225 $ 45 As of June 30, 2018, total unrecognized compensation cost related to the unvested stock‑based awards was $2,562, which is expected to be recognized over a weighted average period of 2.42 years. |
Net loss per share
Net loss per share | 3 Months Ended |
Jun. 30, 2018 | |
Net loss per share | |
Net loss per share | 11. Net loss per share Net loss per share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, 2018 2017 Numerator: Net loss attributable to common stockholders $ (10,044) $ (3,552) Denominator: Weighted average common shares outstanding, basic and diluted 4,981,227 4,973,439 Net loss per share attributable to common stockholders, basic and diluted $ (2.02) $ (0.71) The Company’s potentially dilutive securities, which include stock options, preferred stock and warrants to purchase shares of series seed preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Common A stock has been excluded from the computation of diluted net loss per share because the shares have nominal economic participation rights. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti‑dilutive effect: Three Months Ended June 30, 2018 2017 Options to purchase common stock 2,502,530 930,027 Convertible preferred stock (as converted to common stock) 19,157,360 10,588,977 Warrants to purchase convertible preferred stock (as converted to common stock) 497,344 497,344 22,157,234 12,016,348 |
Significant Agreement
Significant Agreement | 3 Months Ended |
Jun. 30, 2018 | |
Significant Agreements | |
Significant Agreements | 12. Significant Agreements Agreement with Bristol-Myers Squibb Company In February 2018, the Company entered into an agreement with Bristol-Myers Squibb Company ("BMS"). Pursuant to the agreement, BMS will provide to the Company, at no cost, a compound for use in the Company's ongoing clinical trial. Under the agreement, the Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted the Company a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to its compound in the clinical trial and agreed to manufacture and supply its compound, at its cost and for no charge to the Company, for use in the clinical trial. Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated by either party (i) in the event of an uncured material breach by the other party, (ii) in the event the other party is insolvent or in bankruptcy proceedings or (iii) for safety reasons. Upon termination, the licenses granted to the Company to use BMS's compound in the clinical trial will terminate. As of June 30, 2018, the Company had not incurred any costs in connection with this agreement. Agreement with Regeneron Pharmaceuticals, Inc. In May 2018, the Company entered into an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"). The Company and Regeneron are each independently developing compounds for the treatment of certain tumor types. Pursuant to the agreement, the Company and Regeneron will undertake one or more clinical trials using a combination of the compounds being developed by each entity. Under the agreement, each study will be conducted under terms set out in a separately agreed upon study plan that will identify the name of the sponsor and which party will manage the particular clinical trial, and include the protocol, the budget and a schedule of clinical obligations. In June 2018, under the terms of the agreement between the Company and Regeneron, the parties agreed to the first study plan. The Company and Regeneron have agreed to the protocol, budget, sample testing and clinical obligations schedule under the study plan. Development and supply costs associated with the study plan will be split equally between the Company and Regeneron. Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license under its respective intellectual property and agreed to contribute the necessary resources needed to fulfill its respective obligations, in each case, under the terms of the agreed-upon or to-be agreed upon study plans. Development costs of a particular clinical trial will be split equally between the Company and Regeneron. The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed, (ii) the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (iii) in the event of a material breach. The Company will account for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company will recognize any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. As of June 30, 2018, the Company had not incurred any costs or received any reimbursements in connection with this agreement. |
Commitments and contingencies
Commitments and contingencies | 3 Months Ended |
Jun. 30, 2018 | |
Commitments and contingencies | |
Commitments and contingencies | 13. Commitments and contingencies Lease agreements In December 2015, the Company entered into a lease agreement for office space in Woburn, Massachusetts, which expires on March 30, 2021. The Company has the option to extend the lease agreement for successive periods of five years. Monthly lease payments, inclusive of base rent and ancillary charges, total $7. Monthly base rent is subject to increase each year in proportion to the Consumer Price Index. In April 2016, the Company entered into a lease agreement for office and laboratory space in Abingdon, England, which expires on April 3, 2026. The Company has the right to terminate the lease as of April 4, 2021 upon at least nine months’ prior written notice. Monthly lease payments are inclusive of base rent, ancillary charges, non‑rent shared tenant occupancy costs and the respective value added tax to be paid. Monthly lease payments include base rent of approximately $23 through December 3, 2016 and $31 thereafter. Monthly base rent is subject to increase after April 2021 in proportion to the Retail Price Index. In June 2018, the Company entered into an agreement to lease approximately 63,000 square feet of office, manufacturing and laboratory space within a previously occupied building with approximately 106,000 square feet of rentable space in Framingham, Massachusetts. Pursuant to the lease agreement, the lease term is estimated to commence in November 2018, subject to the landlord completing certain agreed upon landlord improvements. The rent commencement date is estimated to be eight months after the commencement of the lease term. The initial lease term is ten years from the rent commencement date and includes two optional five year extensions. Annual lease payments during the first year are $2,373 with increases of 3.0% each year. The Company recorded rent expense of $110 and $103 during the three months ended June 30, 2018 and 2017, respectively. The following table summarizes the future minimum lease payments due under the Company’s operating leases as of June 30, 2018: 2019 (remaining nine months) $ 361 2020 1,474 2021 2,888 $ 4,723 Manufacturing commitments The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of June 30, 2018 and March 31, 2018, the Company had committed to minimum payments under these arrangements totaling $3,298 and $2,938 through June 30, 2019 and March 31, 2019, respectively. Indemnification agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2018 or March 31, 2018. Legal proceedings The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. |
Benefit Plans
Benefit Plans | 3 Months Ended |
Jun. 30, 2018 | |
Benefit Plans | |
Benefit Plans | 14. Benefit plans The Company established a defined‑contribution savings plan under Section 401(k) of the Code (the “401(k) Plan”). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre‑tax basis. Matching contributions to the 401(k) Plan may be made at the discretion of the Company’s board of directors. During the three months ended June 30, 2018 and 2017, the Company made contributions totaling $33 and $14, respectively, to the 401(k) Plan. We provide a pension contribution plan for our employees in the United Kingdom, pursuant to which we match our employees’ contributions each year in amounts up to 8% of their annual base salary. |
Geographical Information
Geographical Information | 3 Months Ended |
Jun. 30, 2018 | |
Geographical Information | |
Geographical Information | 15. Geographic information The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company’s long‑lived assets held in different geographic regions is presented in the tables below: June 30, March 31, 2018 2018 United States $ 18 $ 20 United Kingdon 425 350 $ 443 $ 370 |
Subsequent events
Subsequent events | 3 Months Ended |
Jun. 30, 2018 | |
Subsequent events | |
Subsequent events | 16. Subsequent events Initial Public Offering On July 24, 2018, the Company completed an IPO of its common stock and issued and sold 6,700,000 shares of common stock at a public offering price of $15.00 per share, resulting in net proceeds of $93,465 after deducting underwriting discounts and commissions but before deducting offering costs. Upon closing of the IPO, the Company’s outstanding convertible preferred stock automatically converted into shares of common stock (see Note 7). Upon conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock and additional paid-in capital. In addition, the warrant to purchase shares of the Company’s series seed convertible preferred stock was converted into a warrant to purchase shares of the Company’s common stock upon the closing of the IPO. As a result, the warrant liability will be remeasured a final time on the closing date of the IPO and reclassified to stockholders’ deficit. On July 30, 2018, the Company issued and sold an additional 707,936 shares of its common stock at the IPO price of $15.00 per share pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $9,876 after deducting discounts and commissions and other offering expenses. Also in connection with the completion of its IPO on July 24, 2018, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to authorize the issuance of up to 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. 2018 Omnibus Incentive Compensation Plan On July 9, 2018, the Company’s board of directors adopted and the Company’s stockholders approved the 2018 Omnibus Incentive Compensation Plan (the “2018 Plan”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The 2018 Plan provides for the issuance of incentive stock options, non‑qualified stock options, stock awards, stock units, stock appreciation rights and other stock‑based awards. The number of shares initially reserved for issuance under the 2018 Plan is 3,617,968 shares, which is equal to the sum of (i) 3,486,118 shares of the Company’s common stock, plus (ii) the number of shares of the Company’s common stock reserved for issuance under the 2017 Plan that remain available as of the effective date of the 2018 Plan (not to exceed 131,850 shares of the Company’s common stock). If any options or stock appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock‑based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the Company’s common stock subject to such grants will be available for purposes of our 2018 Plan. Employee Stock Purchase Plan On July 9, 2018, the Company’s board of directors adopted and the Company’s stockholders approved the Employee Stock Purchase Plan (the “ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved for issuance under the ESPP is limited to 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of the ESPP (excluding any extensions), an additional number of shares of the Company’s common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year or 697,224 shares, whichever is less (or such lesser amount as determined by the Company’s board of directors) will be added to the number of shares authorized under the ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the ESPP, then the plan administrator will allocate the available shares pro‑rata and refund any excess payroll deductions or other contributions to participants. |
Summary of significant accoun23
Summary of significant accounting policies (Policies) | 3 Months Ended |
Jun. 30, 2018 | |
Summary of significant accounting policies | |
Principles of consolidation | Principles of consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Replimune UK, Replimune US and Replimune Securities Corporation, after elimination of all intercompany accounts and transactions. The consolidated financial statements reflect the capital as if Replimune Group, Inc. had been in existence for all periods presented. |
Use of estimates | Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock‑based awards. The Company bases its estimates on historical experience, known trends and other market‑specific or other relevant factors that it believe to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. |
Unaudited interim consolidated financial information | Unaudited interim consolidated financial information The accompanying consolidated balance sheet as of June 30, 2018, the consolidated statements of operations, of comprehensive loss and of cash flows for the three months ended June 30, 2018 and 2017 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2018 and the results of its operations and its cash flows for the three months ended June 30, 2018 and 2017. The financial data and other information disclosed in these consolidated notes related to the three months ended June 30, 2018 and 2017 are unaudited. The results for the three months ended June 30, 2018 are not necessarily indicative of results to be expected for the year ending March 31, 2019, any other interim periods or any future year or period. |
Foreign currency and currency translation | Foreign currency and currency translation The functional currency for the Company’s wholly owned foreign subsidiary, Replimune UK, is the British pound. Assets and liabilities of Replimune UK are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of convertible preferred stock and stockholders’ deficit as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations as incurred. |
Concentrations of credit risk and of significant suppliers | Concentrations of credit risk and of significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as short‑term investments. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials. |
Cash and cash equivalents | Cash and cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. Cash equivalents consisted of money market funds at June 30, 2018 and March 31, 2018. As of June 30, 2018 and March 31, 2018, cash equivalents totaled $4,194 and $4,130, respectively. |
Restricted cash | Restricted cash The Company maintains certain minimum balances in segregated bank accounts in connection with its corporate credit cards and a letter of credit for the benefit of the landlords in connection with an operating lease. As of June 30, 2018 and March 31, 2018, restricted cash consisted of $76 and $78, respectively, held in connection with the Company’s corporate credit cards and $1,780 and $0, respectively, held for the benefit of the landlords in connection with an operating lease. These amounts have been classified as non‑current assets on the Company’s consolidated balance sheets. |
Short term investments | Short‑term investments The Company’s short‑term debt security investments are classified as available‑for‑sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ deficit. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations. The Company evaluates its short‑term debt security investments with unrealized losses for other‑than‑temporary impairment. When assessing short‑term debt security investments for other‑than‑temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain the short‑term debt security investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the short‑term debt security investment that the Company considers to be “other than temporary,” the Company reduces the short‑term debt security investment to fair value through a charge to the consolidated statements of operations. No such adjustments were necessary during the periods presented. The Company’s short‑term debt security investments as of June 30, 2018 and March 31, 2018 had original maturities of less than one year. |
Deferred offering costs | Deferred offering costs The Company capitalizes certain legal, professional accounting and other third‑party fees that are directly associated with in‑process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit as a reduction of proceeds generated as a result of the offering. Should an in‑process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. The Company did not record any deferred offering costs as of March 31, 2018. As of June 30, 2018, the Company recorded $1,344 of deferred offering costs in contemplation of a planned initial public offering of common stock. |
Property, plant and equipment | Property, plant and equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight‑line method over the estimated useful lives of the respective assets as follows: Estimated Useful life Office equipment 5 years Computer equipment 3 years Plant and laboratory equipment 5 years Leasehold improvements Lesser of lease term or 10 years Costs for capital assets not yet placed into service are capitalized as construction‑in‑progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. |
Impairment of long lived assets | Impairment of long‑lived assets Long‑lived assets consist of property, plant and equipment. Long‑lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long‑lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long‑lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses on long‑lived assets. |
Deferred rent | Deferred rent The Company recognizes rent expense on a straight‑line basis over the respective lease terms and has recorded deferred rent for rent expense incurred but not yet paid. |
Fair value measurements | Fair value measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: · Level 1—Quoted prices in active markets for identical assets or liabilities. · Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. · Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s short‑term investments, cash equivalents and warrant liability are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of research and development incentives receivable, other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short‑term nature of these assets and liabilities. |
Warrant liability | Warrant liability The Company classifies warrants to purchase shares of series seed preferred stock (see Note 8) as a liability on its consolidated balance sheets as these warrants to purchase shares of series seed preferred stock are free‑standing financial instruments that may require the Company to transfer assets upon exercise. The warrant liability was initially recorded at fair value upon the date of the warrants’ issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Changes in the fair value of the warrant liability will continue to be recognized until the warrants to purchase shares of series seed preferred stock are exercised, expire or qualify for equity classification. The Company utilizes the Black‑Scholes option‑pricing model, which incorporates assumptions and estimates, to value the warrant liability. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the expected stock price volatility, the expected term of the warrant, the risk‑free interest rate for a period that approximates the expected term of the warrant, and the Company’s expected dividend yield (see Note 3). Upon the closing of the IPO, the warrant to purchase shares of the Company’s series seed convertible preferred stock was converted into a warrant to purchase shares of the Company’s common stock. As a result, the warrant liability will be remeasured a final time on the closing date of the IPO and reclassified to stockholders’ deficit. |
Segment information | Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s current focus is on developing oncolytic immunotherapies for the treatment of cancer. |
Research and development costs | Research and development costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock‑based compensation and benefits, facilities costs and laboratory supplies, depreciation and external costs of outside vendors engaged to conduct preclinical development, clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non‑refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. |
Research contract costs and accruals | Research contract costs and accruals The Company has entered into various research and development-related contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. |
Patent costs | Patent costs All patent‑related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. |
Stock-based compensation | Stock‑based compensation The Company measures all stock‑based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black‑Scholes option‑pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk‑free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield (see Note 10). Forfeitures are accounted for as they occur. To date, the Company has issued stock‑based awards with only service‑based vesting conditions and records the expense for these awards using the straight‑line method. For stock‑based awards granted to consultants and non‑employees, compensation expense is recognized over the shorter of the vesting period or the period during which services are rendered by such consultants and non‑employees until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then‑current fair value of the Company’s common stock and updated assumption inputs in the Black‑Scholes option‑pricing model. The Company classifies stock‑based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. |
Research and development incentives and receivable | Research and development incentives and receivable The Company, through its subsidiary in the United Kingdom, receives reimbursements of certain research and development expenditures as part of a United Kingdom government’s research and development tax reliefs program. Under the program, a percentage of qualifying research and development expenses incurred by the Company’s subsidiary in the United Kingdom are reimbursed up to 14.5%. Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time. The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as other income. The research and development incentives receivable represents an amount due in connection with the above program. The Company recorded other income from research and development incentives of $438 and $467 during the three months ended June 30, 2018 and 2017, respectively, in the consolidated statements of operations and a research and development incentives receivable of $2,677 (of which $2,251 was classified as current and $426 was classified as long-term) and $2,389 as of June 30, 2018 and March 31, 2018, respectively, on the consolidated balance sheets. |
Comprehensive loss | Comprehensive loss Comprehensive loss includes net loss as well as other changes in stockholders’ deficit that result from transactions and economic events other than those with stockholders. For the three months ended June 30, 2018 and 2017, comprehensive loss included $(847) and $953 of foreign currency translation adjustments, and $35 and $0 of unrealized gains on short‑term investments, net of tax, respectively. |
Income taxes | Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two‑step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more‑likely‑than‑not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. |
Net income (loss) per share | Net income (loss) per share The Company follows the two‑class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two‑class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two‑class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. Common A shares are excluded when computing net income (loss) per share as they have nominal economic rights. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but contractually do not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti‑dilutive. |
Recently adopted accounting pronouncements | Recently adopted accounting pronouncements In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU 2017-09"), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2017-09 as of the required effective date of April 1, 2018 and will apply to any changes to the terms or conditions of share-based payment awards prospectively. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash ("ASU 2016-18"), which requires restricted cash to be presented with cash and cash equivalents on the consolidated statements of cash flows and disclosure of how the consolidated statements of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-18 as of April 1, 2018. Restricted cash is now included as a component of cash, cash equivalents and restricted cash on the Company's consolidated statement of cash flows. Upon the adoption of ASU 2016-18, the amount of cash and cash equivalents previously presented on the consolidated statements of cash flows will reflect the inclusion of restricted cash in the amount reported for changes in cash, cash equivalents and restricted cash. Additionally, as a result of the adoption, transfers between restricted and unrestricted cash are no longer presented as a component of the Company’s investing activities. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory ("ASU 2016-16"), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-16 as of the required effective date of April 1, 2018. The adoption of ASU 2016-16 did not have a material impact on the Company’s financial position, results of operations or cash flows. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the consolidated statements of cash flows. The standard is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-16 as of the required effective date of April 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which supersedes existing revenue recognition guidance under GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of ASU 2014-09 such that the standard is effective for public entities for annual periods beginning after December 15, 2017 and for interim periods within those fiscal years. Early adoption of the standard is permitted for annual periods beginning after December 15, 2016. The Company adopted ASU 2014-09 on a full retrospective basis effective April 1, 2018. The adoption of ASU 2014-09 did not have an impact on the Company's consolidated financial statements as the Company does not currently have any revenue-generating arrangements. |
Recently issued accounting pronouncements | Recently issued accounting pronouncements In July 2017, the FASB issued ASU No. 2017‑11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017‑11”). Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down‑round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (“ASC”) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017‑11 is required to be adopted for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2017-11 is not expected to have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December 15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. In June 2018, the FASB issued (“ASU 2018-07”), Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-17 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-17 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that ASU 2018-17 will have on our financial position, results of operations, and disclosures. |
Summary of significant accoun24
Summary of significant accounting policies (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Summary of significant accounting policies | |
Schedule of estimated useful life of property, plant and equipment | Estimated Useful life Office equipment 5 years Computer equipment 3 years Plant and laboratory equipment 5 years Leasehold improvements Lesser of lease term or 10 years |
Fair value of financial asset25
Fair value of financial assets and liabilities (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Fair value of financial assets and liabilities | |
Schedule of company's financial assets and liabilities measured at fair value on a recurring basis | Fair Value Measurements as of June 30, 2018 Using: Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 4,194 $ — $ 4,194 Commercial paper — 22,017 — 22,017 Corporate debt securities — 17,102 — 17,102 $ — $ 43,313 $ — $ 43,313 Liabilities: Warrant liability $ — $ — $ 7,092 $ 7,092 $ — $ — $ 7,092 $ 7,092 Fair Value Measurements as of March 31, 2018 Using: Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 4,130 $ — $ 4,130 Commercial paper — 27,998 — 27,998 Corporate debt securities — 15,970 — 15,970 $ — $ 48,098 $ — $ 48,098 Liabilities: Warrant liability $ — $ — $ 1,642 $ 1,642 $ — $ — $ 1,642 $ 1,642 |
Schedule of unobservable inputs of the warrant liability | Three Months Ended June 30, 2017 2018 Risk-free interest rate 2.68 % 1.20 % Expected dividend yield 0 % 0 % Expected term (in years) 7.3 8.3 Expected volatility 64.4 % 75.0 % Fair value of series seed preferred stock $ 15.00 $ 1.68 |
Schedule of roll forward of the warrant liability | Warrant Liability Balance at March 31, 2018 $ 1,642 Change in fair value 5,450 Balance at June 30, 2018 $ 7,092 |
Short-term investments (Tables)
Short-term investments (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Short-term investments | |
Schedule of short-term investments | June 30, 2018 Amortized Gross Unrealized Gross Unrealized Fair cost Gains Losses value Commercial paper $ 22,033 $ 1 $ (17) $ 22,017 Corporate debt securities 17,116 — (14) 17,102 $ 39,149 $ 1 $ (31) $ 39,119 March 31, 2018 Amortized Gross Unrealized Gross Unrealized Fair cost Gains Losses value Commercial paper $ 28,028 $ 2 $ (32) $ 27,998 Corporate debt securities 16,005 — (35) 15,970 $ 44,033 $ 2 $ (67) $ 43,968 |
Property, plant and equipment27
Property, plant and equipment, net (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Property, plant and equipment, net | |
Schedule of property, plant and equipment, net | June 30, March 31, 2018 2018 Leasehold improvements $ 154 $ 154 Office equipment 49 49 Computer equipment 91 87 Plant and laboratory equipment 438 336 732 626 Less: Accumulated depreciation and amortization (289) (256) $ 443 $ 370 |
Accrued expenses and other cu28
Accrued expenses and other current liabilities (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Accrued expenses and other current liabilities | |
Schedule of accrued expenses and other current liabilities | June 30, March 31, 2018 2018 Accrued research and development costs $ 809 $ 949 Accrued compensation and benefits costs 334 949 Accrued professional fees 345 1,094 Deferred rent 25 26 Other 129 153 $ 1,642 $ 3,171 |
Convertible preferred stock (Ta
Convertible preferred stock (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Convertible preferred stock | |
Schedule of convertible preferred stock | June 30, 2018 Preferred Preferred Shares Common Stock Shares Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series Seed preferred stock 250,000 200,000 $ 1,609 $ 2,000 1,989,376 Series A preferred stock 864,553 864,553 30,000 30,000 8,599,601 Series B preferred stock 861,415 861,415 54,752 54,950 8,568,383 1,975,968 1,925,968 $ 86,361 $ 86,950 19,157,360 March 31, 2018 Preferred Preferred Shares Common Stock Shares Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series Seed preferred stock 250,000 200,000 $ 1,609 $ 2,000 1,989,376 Series A preferred stock 864,553 864,553 30,000 30,000 8,599,601 Series B preferred stock 861,415 861,415 54,752 54,950 8,568,383 1,975,968 1,925,968 $ 86,361 $ 86,950 19,157,360 |
Stock-based compensation (Table
Stock-based compensation (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Stock-based compensation | |
Summary of stock option activity | The following table summarizes the Company’s stock option activity: Weighted Weighted Average Number of Average Contractual Aggregate Shares Exercise Price Term (Years) Intrinsic Value Outstanding as of March 31,2018 2,520,247 $ 2.72 8.91 $ 2,808 Cancelled (17,717) 2.62 Outstanding as of June 30, 2018 2,502,530 $ 2.72 8.66 $ 30,736 Options exercisable as of March 31, 2018 592,416 $ 1.84 8.22 $ 1,184 Options exercisable as of June 30, 2018 647,947 $ 1.81 7.95 $ 8,543 Options vested and expected to vest as of March 31, 2018 2,520,247 $ 2.72 8.91 $ 2,808 Options vested and expected to vest as of June 30, 2018 2,502,530 $ 2.72 8.66 $ 30,736 |
Schedule of stock-based compensation expense | Three Months Ended June 30, 2018 2017 Research and development $ 126 $ 21 General and administrative 99 24 Total share based compensation expense $ 225 $ 45 |
Net loss per share (Tables)
Net loss per share (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Net loss per share | |
Schedule of calculation of basic and diluted net loss per share attributable to common stockholders | Three Months Ended June 30, 2018 2017 Numerator: Net loss attributable to common stockholders $ (10,044) $ (3,552) Denominator: Weighted average common shares outstanding, basic and diluted 4,981,227 4,973,439 Net loss per share attributable to common stockholders, basic and diluted $ (2.02) $ (0.71) |
Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders | Three Months Ended June 30, 2018 2017 Options to purchase common stock 2,502,530 930,027 Convertible preferred stock (as converted to common stock) 19,157,360 10,588,977 Warrants to purchase convertible preferred stock (as converted to common stock) 497,344 497,344 22,157,234 12,016,348 |
Commitments and contingencies (
Commitments and contingencies (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Commitments and contingencies | |
Schedule of future minimum lease payments under non cancelable operating lease commitments | 2019 (remaining nine months) $ 361 2020 1,474 2021 2,888 $ 4,723 |
Geographical Information (Table
Geographical Information (Tables) | 3 Months Ended |
Jun. 30, 2018 | |
Geographical Information | |
Summary of company's long-lived assets held in different geographic regions | June 30, March 31, 2018 2018 United States $ 18 $ 20 United Kingdon 425 350 $ 443 $ 370 |
Nature of the business (Details
Nature of the business (Details) $ / shares in Units, $ in Thousands | Jul. 30, 2018USD ($)$ / sharesshares | Jul. 24, 2018USD ($)$ / sharesshares | Jul. 09, 2018shares | Jul. 10, 2017 | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Mar. 31, 2018USD ($)$ / sharesshares |
Shares issued in exchange of shares in Replimune Group, Inc | 1 | ||||||
Ratio of replacement warrants to capital stock | 1 | ||||||
Net loss | $ | $ (10,044) | $ (3,552) | |||||
Accumulated deficit | $ | $ (38,976) | $ (28,932) | |||||
Common stock, authorized | 27,314,288 | 27,314,288 | |||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||
Subsequent events | |||||||
Forward stock split ratio for each common stock | 0.100534 | ||||||
Common stock, authorized | 27,314,288 | ||||||
Subsequent events | IPO | |||||||
Shares issued | 707,936 | 6,700,000 | |||||
Shares issued price (in dollars per share) | $ / shares | $ 15 | $ 15 | |||||
Proceeds from issuance of initial public offering | $ | $ 9,876 | $ 93,465 | |||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | ||||||
Undesignated preferred stock, authorized | 10,000,000 | ||||||
Preferred stock, Par Value (in dollars per share) | $ / shares | $ 0.001 | ||||||
Subsequent events | IPO | Maximum | |||||||
Common stock, authorized | 150,000,000 |
Summary of significant accoun35
Summary of significant accounting policies (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Mar. 31, 2018 | |
Summary of significant accounting policies | |||
Money market funds | $ 4,194 | $ 4,130 | |
Restricted cash | 1,856 | 78 | |
Deferred offering costs | 1,344 | ||
Research and development incentives | 438 | $ 467 | |
Research and development incentives receivable | 2,251 | 2,389 | |
Research and development incentives receivable - long term | 426 | ||
Foreign currency translation gain (loss) | (847) | $ 953 | |
Net unrealized gain on short-term investments, net of tax | $ 35 | ||
Minimum percentage of benefit recognized is being realized upon ultimate settlement | 50.00% | ||
Revenues | $ 0 | ||
Credit cards | |||
Summary of significant accounting policies | |||
Restricted cash | 76 | 78 | |
Operating lease | |||
Summary of significant accounting policies | |||
Restricted cash | $ 1,780 | $ 0 | |
Maximum | United Kingdom | |||
Summary of significant accounting policies | |||
Percentage of qualifying research and development expenses reimbursed by government | 14.50% | ||
Office equipment | |||
Summary of significant accounting policies | |||
Estimated Useful life's of property, plant and equipment (in years) | 5 years | ||
Computer equipment | |||
Summary of significant accounting policies | |||
Estimated Useful life's of property, plant and equipment (in years) | 3 years | ||
Plant and laboratory equipment | |||
Summary of significant accounting policies | |||
Estimated Useful life's of property, plant and equipment (in years) | 5 years | ||
Leasehold improvements | |||
Summary of significant accounting policies | |||
Estimated Useful life's of property, plant and equipment (in years) | 10 years |
Fair value of financial asset36
Fair value of financial assets and liabilities (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Jun. 30, 2018 | |
Fair value of financial assets and liabilities | |||
Transfer from Leve 2 to Level 1, assets | $ 0 | $ 0 | |
Transfers into Level 3, assets | 0 | 0 | |
Transfer out of Level 3, assets | 0 | 0 | |
Transfer from Leve 1 to Level 2, liabilities | 0 | 0 | |
Transfer from Leve 2 to Level 1, liabilities | 0 | 0 | |
Transfers into Level 3, liabilities | 0 | 0 | |
Transfer out of Level 3, liabilities | 0 | $ 0 | |
Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 48,098 | $ 43,313 | |
Liabilities fair value | 1,642 | 7,092 | |
Level 2 | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 48,098 | 43,313 | |
Level 3 | Recurring | |||
Fair value of financial assets and liabilities | |||
Liabilities fair value | 1,642 | 7,092 | |
Money market funds | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 4,130 | 4,194 | |
Money market funds | Level 2 | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 4,130 | 4,194 | |
Commercial paper | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 27,998 | 22,017 | |
Commercial paper | Level 2 | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 27,998 | 22,017 | |
Corporate debt securities | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 15,970 | 17,102 | |
Corporate debt securities | Level 2 | Recurring | |||
Fair value of financial assets and liabilities | |||
Assets fair value | 15,970 | 17,102 | |
Warrant liability | Recurring | |||
Fair value of financial assets and liabilities | |||
Liabilities fair value | 1,642 | 7,092 | |
Warrant liability | Level 3 | Recurring | |||
Fair value of financial assets and liabilities | |||
Liabilities fair value | $ 1,642 | $ 7,092 |
Fair value of financial asset37
Fair value of financial assets and liabilities - Unobservable inputs of the warrant liability (Details) | 3 Months Ended | |
Jun. 30, 2018item$ / shares | Jun. 30, 2017item$ / shares | |
Risk-free interest rate | ||
Unobservable inputs of the warrant liability | ||
Warrant liability inputs | 2.68 | 1.20 |
Expected dividend yield | ||
Unobservable inputs of the warrant liability | ||
Warrant liability inputs | 0 | 0 |
Expected term | ||
Unobservable inputs of the warrant liability | ||
Warrant liability expected term (in years) | 7 years 3 months 18 days | 8 years 3 months 18 days |
Expected volatility | ||
Unobservable inputs of the warrant liability | ||
Warrant liability inputs | 64.4 | 75 |
Fair value of series seed preferred stock | ||
Unobservable inputs of the warrant liability | ||
Warrant liability fair value of series seed preferred stock (in dollars per share) | $ / shares | $ 15 | $ 1.68 |
Fair value of financial asset38
Fair value of financial assets and liabilities - Roll forward of the warrant liability (Details) - Warrant liability $ in Thousands | 3 Months Ended |
Jun. 30, 2018USD ($) | |
Roll forward of the warrant liability | |
Balance at beginning of the period | $ 1,642 |
Change in fair value | 5,450 |
Balance at end of the period | $ 7,092 |
Short-term investments (Details
Short-term investments (Details) - Short-term investments - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Mar. 31, 2018 | |
Short-term investments | ||
Amortized cost | $ 39,149 | $ 44,033 |
Gross unrealized gains | 1 | 2 |
Gross unrealized losses | (31) | (67) |
Fair value | 39,119 | 43,968 |
Commercial paper | ||
Short-term investments | ||
Amortized cost | 22,033 | 28,028 |
Gross unrealized gains | 1 | 2 |
Gross unrealized losses | (17) | (32) |
Fair value | 22,017 | 27,998 |
Corporate debt securities | ||
Short-term investments | ||
Amortized cost | 17,116 | 16,005 |
Gross unrealized losses | (14) | (35) |
Fair value | $ 17,102 | $ 15,970 |
Property, plant and equipment40
Property, plant and equipment, net (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Mar. 31, 2018 | |
Property, plant and equipment, net | |||
Property, plant and equipment , gross | $ 732 | $ 626 | |
Less: Accumulated depreciation and amortization | (289) | (256) | |
Property, plant and equipment , net | 443 | 370 | |
Depreciation and amortization expense | 33 | $ 23 | |
Leasehold improvements | |||
Property, plant and equipment, net | |||
Property, plant and equipment , gross | 154 | 154 | |
Office equipment | |||
Property, plant and equipment, net | |||
Property, plant and equipment , gross | 49 | 49 | |
Computer equipment | |||
Property, plant and equipment, net | |||
Property, plant and equipment , gross | 91 | 87 | |
Plant and laboratory equipment | |||
Property, plant and equipment, net | |||
Property, plant and equipment , gross | $ 438 | $ 336 |
Accrued expenses and other cu41
Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 |
Accrued expenses and other current liabilities | ||
Accrued research and development costs | $ 809 | $ 949 |
Accrued compensation and benefits costs | 334 | 949 |
Accrued professional fees | 345 | 1,094 |
Deferred rent | 25 | 26 |
Other | 129 | 153 |
Total | $ 1,642 | $ 3,171 |
Convertible preferred stock (De
Convertible preferred stock (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 |
Convertible preferred stock | ||
Conversion ratio (in shares) | 0.100534 | |
Preferred shares authorized (in shares) | 1,975,968 | 1,975,968 |
Preferred shares issued (in shares) | 1,925,968 | 1,925,968 |
Preferred shares outstanding (in shares) | 1,925,968 | 1,925,968 |
Convertible preferred stock (as converted to common stock) | ||
Convertible preferred stock | ||
Preferred shares authorized (in shares) | 1,975,968 | 1,975,968 |
Preferred shares issued (in shares) | 1,925,968 | 1,925,968 |
Preferred shares outstanding (in shares) | 1,925,868 | 1,925,968 |
Carrying value | $ 86,361 | $ 86,361 |
Liquidation preference | $ 86,950 | $ 86,950 |
Common stock issuable upon conversion (in shares) | 19,157,360 | 19,157,360 |
Series Seed preferred stock | ||
Convertible preferred stock | ||
Preferred shares authorized (in shares) | 250,000 | 250,000 |
Preferred shares issued (in shares) | 200,000 | 200,000 |
Preferred shares outstanding (in shares) | 200,000 | 200,000 |
Carrying value | $ 1,609 | $ 1,609 |
Liquidation preference | $ 2,000 | $ 2,000 |
Common stock issuable upon conversion (in shares) | 1,989,376 | 1,989,376 |
Series A preferred stock | ||
Convertible preferred stock | ||
Preferred shares authorized (in shares) | 864,553 | 864,553 |
Preferred shares issued (in shares) | 864,553 | 864,553 |
Preferred shares outstanding (in shares) | 864,553 | 864,553 |
Carrying value | $ 30,000 | $ 30,000 |
Liquidation preference | $ 30,000 | $ 30,000 |
Common stock issuable upon conversion (in shares) | 8,599,601 | 8,599,601 |
Series B preferred stock | ||
Convertible preferred stock | ||
Preferred shares authorized (in shares) | 861,415 | 861,415 |
Preferred shares issued (in shares) | 861,415 | 861,415 |
Preferred shares outstanding (in shares) | 861,415 | 861,415 |
Carrying value | $ 54,752 | $ 54,752 |
Liquidation preference | $ 54,950 | $ 54,950 |
Common stock issuable upon conversion (in shares) | 8,568,383 | 8,568,383 |
Convertible preferred stock rig
Convertible preferred stock rights and preferences (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2018USD ($)director$ / sharesshares | Mar. 31, 2018USD ($)$ / sharesshares | Jun. 30, 2017shares | |
Voting | |||
Number of directors to be elected | director | 2 | ||
Convertible preferred stock (as converted to common stock) | |||
Conversion | |||
Outstanding preferred stock held for conversion (as a percent) | 75.00% | ||
Conversion ratio (in shares) | shares | 19,157,360 | 19,157,360 | |
Dividends | |||
Dividends declared (in dollars per share) | $ 0 | $ 0 | |
Dividends paid | $ | $ 0 | $ 0 | |
Series Seed preferred stock | |||
Voting | |||
Number of directors to be elected | director | 2 | ||
Conversion | |||
Share price (in dollars per share) | $ 1.01 | $ 1.01 | |
Conversion ratio (in shares) | shares | 1,989,376 | 1,989,376 | |
Conversion price (in dollars per share) | $ 10 | $ 10 | |
Series A preferred stock | |||
Voting | |||
Number of directors to be elected | director | 1 | ||
Conversion | |||
Share price (in dollars per share) | $ 3.49 | $ 3.49 | |
Conversion ratio (in shares) | shares | 8,599,601 | 8,599,601 | |
Conversion price (in dollars per share) | $ 34.70 | $ 34.70 | |
Liquidation preference | |||
Liquidation preference (in dollars per share) | $ 69.40 | ||
Series B preferred stock | |||
Voting | |||
Number of directors to be elected | director | 2 | ||
Outstanding preferred stock held (as a percent) | 55.00% | ||
Conversion | |||
Share price (in dollars per share) | $ 6.41 | $ 6.41 | |
Outstanding preferred stock held relating to liquidation preference (as a percent) | 55.00% | ||
Conversion ratio (in shares) | shares | 8,568,383 | 8,568,383 | |
Conversion price (in dollars per share) | $ 63.79 | $ 63.79 | |
Liquidation preference | |||
Liquidation preference (in dollars per share) | $ 127.58 | ||
Common stock | |||
Conversion | |||
Conversion ratio (in shares) | shares | 9.94688 | 9.94688 | |
Common stock | IPO | |||
Conversion | |||
Gross proceeds | $ | $ 30,000 | ||
Share price (in dollars per share) | $ 9.62 |
Preferred stock warrants (Detai
Preferred stock warrants (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Mar. 31, 2018 | |
Preferred stock warrants | |||
Fair value of the warrant liability | $ 7,092 | $ 1,642 | |
Loss from change in fair value of the warrant liability | $ 5,450 | ||
Series Seed preferred stock | |||
Preferred stock warrants | |||
Number of preferred stock warrants issued | 50,000 | ||
Exercise price (in dollars per share) | $ 10 | ||
Fair value of the warrants to purchase shares of series seed preferred stock | $ 391 | ||
Other income (expense), net | |||
Preferred stock warrants | |||
Loss from change in fair value of the warrant liability | $ 5,450 | $ 0 |
Common stock (Details)
Common stock (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | |
Jul. 31, 2017$ / sharesshares | Jun. 30, 2018USD ($)directorVote$ / sharesshares | Mar. 31, 2018$ / sharesshares | |
Common stock | |||
Shares authorized (in shares) | 27,314,288 | 27,314,288 | |
Par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |
Common stock | |||
Common stock | |||
Shares authorized (in shares) | 27,314,288 | 27,314,288 | |
Par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |
Common stock reserved for the conversion of outstanding shares of preferred stock | 22,306,801 | 22,306,801 | |
Number of vote per share | Vote | 1 | ||
Number of directors to be elected | director | 2 | ||
Cash dividends declared (in dollars per share) | $ / shares | $ 0 | ||
Cash dividends paid | $ | $ 0 | ||
Common A stock | |||
Common stock | |||
Shares authorized (in shares) | 26,258 | 26,258 | |
Par value (in dollars per share) | $ / shares | $ 0.001 | ||
Shares issued and sold (in shares) | 26,258 | ||
Maximum | Common A stock | |||
Common stock | |||
Dividends to be received upon declaration (as a percent) | 100.00% | ||
Dividends to be received upon deemed liquidation (as a percent) | 300.00% |
Stock based compensation (Detai
Stock based compensation (Details) - 2017 Plan | 3 Months Ended |
Jun. 30, 2018shares | |
Share based payments | |
Total number of common shares authorized to issue | 2,659,885 |
Number of shares available for grant | 149,567 |
Exercise price for persons holding more than ten percent of voting power (as a percent) | 110.00% |
Expiration period for persons holding more than ten percent of voting power | 10 years |
Share based payment award expiration period | 10 years |
Share based payment award vesting period | 4 years |
Maximum | |
Share based payments | |
Exercise price for persons holding ten percent of voting power (as a percent) | 100.00% |
Expiration period for persons holding ten percent of voting power | 5 years |
Stock based compensation - Stoc
Stock based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | Mar. 31, 2018 | |
Number of shares | |||
Outstanding at beginning of the period (in shares) | 2,520,247 | ||
Cancelled (in shares) | (17,717) | ||
Outstanding at end of the period (in shares) | 2,502,530 | 2,520,247 | |
Options exercisable (in shares) | 647,947 | 592,416 | |
Options vested and expected to vest (in shares) | 2,502,530 | 2,520,247 | |
Weighted average exercise price | |||
Outstanding at beginning of the period (in dollars per share) | $ 2.72 | ||
Cancelled (in dollars per share) | 2.62 | ||
Outstanding at end of the period (in dollars per share) | 2.72 | $ 2.72 | |
Options exercisable (in dollars per share) | 1.81 | 1.84 | |
Options vested and expected to vest (in dollars per share) | $ 2.72 | $ 2.72 | |
Weighted average contractual term (years) | |||
Outstanding (years) | 8 years 7 months 28 days | 8 years 10 months 28 days | |
Options exercisable (years) | 7 years 11 months 12 days | 8 years 2 months 19 days | |
Options vested and expected to vest (years) | 8 years 7 months 28 days | 8 years 10 months 28 days | |
Aggregate intrinsic value | |||
Outstanding at beginning of the period | $ 2,808 | ||
Outstanding at end of the period | 30,736 | $ 2,808 | |
Options exercisable | 8,543 | 1,184 | |
Options vested and expected to vest | 30,736 | $ 2,808 | |
Total fair value of options vested | $ 45 | $ 64 | |
Outstanding unvested service-based stock options | 0 |
Stock based compensation - Clas
Stock based compensation - Classification of expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Share-Based Compensation | ||
Total share based compensation expense | $ 225 | $ 45 |
Total unrecognized compensation cost | $ 2,562 | |
Expenses expected to be recognized over a weighted average remaining period | 2 years 5 months 1 day | |
Research and development expenses | ||
Share-Based Compensation | ||
Total share based compensation expense | $ 126 | 21 |
General and administrative expenses | ||
Share-Based Compensation | ||
Total share based compensation expense | $ 99 | $ 24 |
Net loss per share (Details)
Net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Numerator: | ||
Net loss attributable to common stockholders | $ (10,044) | $ (3,552) |
Denominator: | ||
Weighted average common shares outstanding basic and diluted | 4,981,227 | 4,973,439 |
Net loss per share attributable to common stockholders, basic and diluted | $ (2.02) | $ (0.71) |
Net loss per share - Computatio
Net loss per share - Computation of diluted net loss per share attributable to common stockholders (Details) - shares | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Diluted net loss per share attributable to common stockholders | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 22,157,234 | 12,016,348 |
Options to purchase common stock | ||
Diluted net loss per share attributable to common stockholders | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 2,502,530 | 930,027 |
Convertible preferred stock (as converted to common stock) | ||
Diluted net loss per share attributable to common stockholders | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 19,157,360 | 10,588,977 |
Warrants to purchase shares of series seed preferred stock (as converted to common stock) | ||
Diluted net loss per share attributable to common stockholders | ||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 497,344 | 497,344 |
Commitments and contingencies -
Commitments and contingencies - Lease agreements (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 19 Months Ended | |||
Jun. 30, 2018USD ($)ft²Option | Apr. 30, 2016 | Dec. 31, 2015USD ($) | Jun. 30, 2018USD ($)ft² | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | Jun. 30, 2018USD ($)ft² | |
Lease agreements | |||||||
Number of options to extend lease agreement (in years) | 5 years | ||||||
Monthly lease payments, inclusive of base rent and ancillary charges | $ 7 | ||||||
Prior notice period upon termination of lease | 9 months | ||||||
Base rent of monthly lease payments | $ 23 | $ 31 | |||||
Rent expense | $ 110 | $ 103 | |||||
Leased office space | ft² | 63,000 | ||||||
Lease rent commencement duration | 8 months | ||||||
Rentable office space | ft² | 106,000 | 106,000 | 106,000 | ||||
Lease term | 10 years | 10 years | 10 years | ||||
Number of options to renewal the lease | Option | 2 | ||||||
Renewal period of lease | 5 years | 5 years | 5 years | ||||
Annual rental payment | $ 2,373 | ||||||
Percentage of annual increase in lease rental expenses | 3.00% | 3.00% | 3.00% |
Commitments and contingencies52
Commitments and contingencies - Future minimum lease payments due under the Company's operating leases (Details) $ in Thousands | Jun. 30, 2018USD ($) |
Future minimum lease payments due under the Company's operating leases | |
2,019 | $ 361 |
2,020 | 1,474 |
2,021 | 2,888 |
Total | $ 4,723 |
Commitments and contingencies53
Commitments and contingencies - Manufacturing commitments (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 |
Commitments and contingencies | ||
Minimum payments committed to manufacturing organization | $ 3,298 | $ 2,938 |
Benefit Plans (Details)
Benefit Plans (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
401(k) Plan | ||
Benefit Plans | ||
Contributions to the plan | $ 33 | $ 14 |
Pension Plan | ||
Benefit Plans | ||
Maximum percentage of contribution by employee of their annual base salary | 8.00% |
Geographical Information (Detai
Geographical Information (Details) $ in Thousands | 3 Months Ended | |
Jun. 30, 2018USD ($)item | Mar. 31, 2018USD ($) | |
Geographical Information | ||
Number of operating geographic regions | item | 2 | |
Long-lived assets | $ 443 | $ 370 |
United States | ||
Geographical Information | ||
Long-lived assets | 18 | 20 |
United Kingdom | ||
Geographical Information | ||
Long-lived assets | $ 425 | $ 350 |
Subsequent events (Details)
Subsequent events (Details) - USD ($) $ / shares in Units, $ in Thousands | Jul. 30, 2018 | Jul. 24, 2018 | Jul. 09, 2018 | Jun. 30, 2018 | Mar. 31, 2018 |
Subsequent events | |||||
Common stock, authorized | 27,314,288 | 27,314,288 | |||
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | |||
2017 Plan | |||||
Share based payments | |||||
Total number of common shares authorized to issue | 2,659,885 | ||||
Number of shares available for grant | 149,567 | ||||
Subsequent events | |||||
Subsequent events | |||||
Common stock, authorized | 27,314,288 | ||||
Subsequent events | 2018 Plan | |||||
Share based payments | |||||
Total number of common shares authorized to issue | 3,617,968 | ||||
Common stock reserved for issuance | 3,486,118 | ||||
Number of shares available for grant | 131,850 | ||||
Subsequent events | ESPP | |||||
Share based payments | |||||
Common stock reserved for issuance | 348,612 | ||||
Share based payment award percentage of outstanding shares | 1.00% | ||||
Additional number of common shares authorized to issue | 697,224 | ||||
Subsequent events | 2017 Plan | Maximum | |||||
Share based payments | |||||
Number of shares available for grant | 2,520,247 | ||||
Subsequent events | IPO | |||||
Subsequent events | |||||
Shares issued | 707,936 | 6,700,000 | |||
Shares issued price (in dollars per share) | $ 15 | $ 15 | |||
Proceeds from issuance of initial public offering | $ 9,876 | $ 93,465 | |||
Common stock, par value (in dollars per share) | $ 0.001 | ||||
Undesignated preferred stock, authorized | 10,000,000 | ||||
Preferred stock, Par Value (in dollars per share) | $ 0.001 | ||||
Subsequent events | IPO | Maximum | |||||
Subsequent events | |||||
Common stock, authorized | 150,000,000 |